Table 1.
Socio-demographic, clinical and phylogenetic characteristics of 461 patients diagnosed with XDR-TB in the Western Cape Province of South Africa, 2006–2017
|
N (%) |
||
|---|---|---|
|
Gendera |
Male |
252 (54.7) |
|
Female |
207 (44.9) |
|
|
Ageb |
0–19 years |
32 (6.9) |
|
20–29 years |
128 (27.8) |
|
|
30–39 years |
147 (31.9) |
|
|
40–49 years |
82 (17.8) |
|
|
50–69 years |
54 (11.7) |
|
|
Health (sub)districtc |
Cape Winelands |
33 (7.2) |
|
Garden Route |
31 (6.7) |
|
|
Overberg |
9 (2.0) |
|
|
West Coast |
14 (3.0) |
|
|
Cape Town |
314 (68.1) |
|
|
Eastern |
28 (8.9) |
|
|
Southern |
26 (8.3) |
|
|
Western |
38 (12.1) |
|
|
Northern |
11 (3.5) |
|
|
Khayelitsha |
54 (17.2) |
|
|
Klipfontein |
32 (10.2) |
|
|
Mitchells Plain |
38 (12.1) |
|
|
Tygerberg |
44 (14.0) |
|
|
Centralized hospital or prison |
43 (13.7) |
|
|
Molecular drug resistance profile |
Resistant to INH, RIF, FQ and AMK or KM +ETO +EMB+ETO +PZA+ETO +EMB+SM +EMB+PZA +EMB+PZA+ETO +EMB+PZA+SM +EMB+SM+ETO +PZA+SM+ETO +EMB+PZA+SM+ETO +EMB+PZA+SM+ ETO+LZD |
461 (100.0) 8 (1.7) 57 (12.4) 1 (0.2) 1 (0.2) 2 (0.4) 30 (6.5) 19 (4.1) 4 (0.9) 1 (0.2) 330 (71.6) 8 (1.7) |
|
Year diagnosedd |
2006–2009 |
84 (18.2) |
|
2010–2013 |
198 (43.0) |
|
|
2014–2017 |
178 (38.6) |
|
|
Lineage |
Lineage 2 |
429 (93.1) |
|
Lineage 2.2.1 |
124 (28.9) |
|
|
Lineage 2.2.2 |
305 (71.1) |
|
|
Lineage 4 |
32 (6.9) |
|
|
Lineage 4.1 |
19 (59.4) |
|
|
Lineage 4.3 |
9 (28.1) |
|
|
Lineage 4.4 |
3 (9.4) |
|
|
Lineage 4.8 |
1 (3.1) |
|
Missing data on agender (n=2), bage (n=18), chealth (sub)district (n=60), dyear diagnosed (n=1).
ETO, ethionamide; EMB, ethambutol; PZA, pyrazinamide; SM, streptomycin; LZD, linezolid.